Stocktoria
Medpace Holdings, Inc. MEDP
Medpace Holdings, Inc. (MEDP) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $2.5B at a 17.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-07-24 | Mizuho | Outperform (main) |
| 2026-07-24 | BMO Capital | Market Perform (main) |
| 2026-07-24 | Truist Securities | Hold (main) |
| 2026-07-24 | TD Cowen | Hold (main) |
| 2026-07-24 | RBC Capital | Outperform (main) |
| 2026-07-24 | Baird | Neutral (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | -0.179 |
| Retained earnings / assets | -0.233 |
| EBIT / assets | 0.271 |
| Equity / liabilities | 0.303 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| MEDP | Medpace Holdings, Inc. | 6/9 | 0.2 | 33.4 | +20% |
| CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | 4/9 | 1.81 | — | -0.9% |
| NRC | NRC HEALTH | 3/9 | 0.03 | — | -4% |
| OABI | OmniAb, Inc. | 1/9 | 6 | — | -29.3% |
| BIAF | bioAffinity Technologies, Inc. | 3/9 | — | — | — |
| ABSI | Absci Corp | 2/9 | -1.9 | — | — |
| ISPC | iSpecimen Inc. | 3/9 | — | — | — |
About Medpace Holdings, Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
FAQ
Is MEDP financially healthy?
Medpace Holdings, Inc.'s Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does MEDP pay a dividend?
No, Medpace Holdings, Inc. does not currently pay a dividend.
How profitable is MEDP?
In FY2025, Medpace Holdings, Inc. had a net margin of 17.8% and a return on equity of 98.3%.
Is MEDP overvalued or undervalued?
Medpace Holdings, Inc. trades at about 39.1× trailing earnings — above its 10-year norm (10-year range 27.6×–94.3×, median 34.6×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for MEDP?
The average Wall-Street price target for Medpace Holdings, Inc. is $581.83, about 2.5% below the recent price, from 12 analysts (consensus: hold).
Is MEDP a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Medpace Holdings, Inc.: a Piotroski F-score of 6/9, an Altman Z″ in the distress zone, a P/E of about 33.4×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.